Johnson & Johnson is still facing many lawsuits that threaten its business. It may face additional challenges from patent cliffs and regulatory changes. Despite that, the drugmaker has important ...

Johnson & Johnson must pay more than $42 million to a Massachusetts man who alleges that he developed mesothelioma, a rare ...

New Brunswick, New Jersey-based Johnson & Johnson (JNJ) primarily focuses on drug discovery and manufacturing but has a ...

The big appeal of Johnson & Johnson over the years has been that it's a relatively safe stock to own, and it also offers an attractive dividend yield of 2.8% -- the S&P 500 average is just over 1.5%.

Johnson & Johnson’s revenue growth of 16% to $95 billion over the last twelve months, compared to $82 billion in 2019, 2. a 1.5% fall in its total shares outstanding to 2.6 billion, partly ...

Johnson & Johnson (JNJ 0.44%) is an iconic global healthcare company. It was originally formed in 1866 when three brothers (Robert, Edward, and James Johnson) founded the company to focus on ...

Johnson & Johnson’s easy-to-deliver Covid-19 shot is the vaccine of choice for much of the developing world. Yet the American company, which has already fallen far behind on its deliveries to ...

Johnson & Johnson shares climbed Friday after the conglomerate behind Band-Aid, Neutrogena and a coronavirus vaccine announced plans to split into two companies. (Richard Drew/AP) ...

Johnson & Johnson spun off liabilities — including roughly 38,000 lawsuits — linked to claims of asbestos contamination in its baby powder to a new firm, which then declared bankruptcy.

Johnson & Johnson’s Covid-19 single-shot vaccine was shown to be 66% effective in preventing moderate and severe disease in a global Phase 3 trial, but 85% effective against severe disease, the ...